US FDA grants accelerated approval for Iovance's skin cancer cell therapy (updated)

Iovance Biotherapeutics

16/02/2024 21:04

(Rewrites paragraph 1 to highlight therapy milestone, adds more
details in subsequent paragraphs)
       Feb 16 (Reuters) - Iovance Biotherapeutics  IOVA.O  said
on Friday the U.S. health regulator had granted accelerated
approval for its cell therapy for adult patients with advanced
melanoma, the first such treatment to be approved for the
deadliest form of skin cancer. 
    The agency's nod is for use of the therapy in patients where
the cancer is unable to be removed with surgery or has spread to
other parts of the body that previously has been treated with
other therapies. 
    Lifileucel, sold under the brand name, Amtagvi, is a
tumor-derived T cell immunotherapy composed of a patient's own T
cells, a type of cell that helps the immune system fight cancer.

 (Reporting by Pratik Jain in Bengaluru; Editing by Shinjini
Ganguli and Anil D'Silva)
 ((Pratik.Jain@thomsonreuters.com;))